Loading
Life sciences · Observational Study
ClinicalTrials.gov · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Observational Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07914764). This is a study registration, not published results. Lead sponsor: Nanjing First Hospital, Nanjing Medical University. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 20 participants (ESTIMATED). Conditions: Medullary Thyroid Carcinoma, Small Cell Lung Cancer ( SCLC ), Gastric Adenocarcinoma. Interventions: DIAGNOSTIC_TEST: Intravenous injection of 68Ga-YQ-CC05 for PET-CT examination. Primary outcome measures: SUVmax of lesion uptake value , 60 minutes after administration. Brief summary: Evaluate the safety of the novel radioactive nuclide-labeled cholecystokinin receptor (CCK2R) targeted molecular probe, 68Ga-YQ-CC05, in clinical application, and verify its effectiveness in tumor diagnosis.